摘要 |
The present application relates to methods of screening Glu-GLP1 dual agonists (GGDAs) that activate alternative intracellular signalling pathways through the Glucagon receptor (Glu R). Compounds have been identified as partial agonists rather than full agonists, eliciting a submaximal response, presumably caused by generation of an alternative conformational state of the receptor induced by the ligand-receptor interaction. The compounds may be useful in the treatment of metabolic diseases, e.g., diabetes, obesity, and related glucose metabolism diseases, or other conditions characterized by excess body weight. |
申请人 |
ZEALAND PHARMA A/S;JUST, RASMUS;LOECHEL, STEVEN, CHARLES;OESTERLUND, TORBEN;RIBER, DITTE;FOSGERAU, KELD |
发明人 |
JUST, RASMUS;LOECHEL, STEVEN, CHARLES;OESTERLUND, TORBEN;RIBER, DITTE;FOSGERAU, KELD |